Long-term prognostic value of Duke treadmill scare and exercise thallium-201 imaging performed one to three years after percutaneous transluminal coronary angioplasty

Citation
Kt. Ho et al., Long-term prognostic value of Duke treadmill scare and exercise thallium-201 imaging performed one to three years after percutaneous transluminal coronary angioplasty, AM J CARD, 84(11), 1999, pp. 1323-1327
Citations number
25
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
AMERICAN JOURNAL OF CARDIOLOGY
ISSN journal
00029149 → ACNP
Volume
84
Issue
11
Year of publication
1999
Pages
1323 - 1327
Database
ISI
SICI code
0002-9149(199912)84:11<1323:LPVODT>2.0.ZU;2-Z
Abstract
The value of exercise nuclear perfusion imaging performed beyond the 6-mont h restenosis window for percutaneous transluminal coronary angioplasty (PTC A) has not been explored. This study evaluates the long-term prognostic val ue of exercise thallium (Tl)-201 imaging after PTCA. We studied the late ou tcome of a series of 211 patients with tomographic Tl-201 exercise studies performed between 1 to 3 years after PTCA. Follow-up was 96% complete at a median duration of 7.3 years. Most (73%) had 1- or 2-vessel coronary artery disease and normal left ventricular function and 193 (91%) had successful PTCA. Two thirds of the patients were symptomatic at the time of testing. T he mean Duke score was 5 +/- 6 and 125 (60%) patients had a low-risk Dyke s core. Mean summed stress score was 50 +/- 9 and mean summed reversibility s core was 3 +/- 4. The 5-year overall survival wets 95%, yielding a low annu al mortality rate of 1%/year. The summed stress score exhibited a significa nt association (9 = 0.047) with the end point of cardiac death or myocardia l infarction. The Duke score was predictive of the combination end point of hard and soft cardiac events (p = 0.002). This study demonstrates that exe rcise Tl-201 perfusion imaging performed 1 to 3 years after PTCA was predic tive of cardiac events. (C) 1999 by Excerpta Medica, Inc.